EA200701636A1 - Производные n-гидроксиамида и их применение - Google Patents

Производные n-гидроксиамида и их применение

Info

Publication number
EA200701636A1
EA200701636A1 EA200701636A EA200701636A EA200701636A1 EA 200701636 A1 EA200701636 A1 EA 200701636A1 EA 200701636 A EA200701636 A EA 200701636A EA 200701636 A EA200701636 A EA 200701636A EA 200701636 A1 EA200701636 A1 EA 200701636A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydroxyamide
derivatives
diseases
fibrosis
application
Prior art date
Application number
EA200701636A
Other languages
English (en)
Other versions
EA014238B1 (ru
Inventor
Доминик Свиннен
Жером Гонзалес
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of EA200701636A1 publication Critical patent/EA200701636A1/ru
Publication of EA014238B1 publication Critical patent/EA014238B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к производным N-гидроксиамида формулы (I) и их применению в особенности для лечения и/или профилактики аутоиммунных расстройств, воспалительных заболеваний, сердечно-сосудистых заболеваний, нейродегенеративных заболеваний, рака, респираторных заболеваний и фиброза, включая рассеянный склероз, артрит, эмфизему, хроническую обструктивную болезнь легких, а также фиброз печени и легких.
EA200701636A 2005-01-31 2006-01-27 Производные n-гидроксиамида и их применение EA014238B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05100646 2005-01-31
US64893105P 2005-02-01 2005-02-01
PCT/EP2006/050480 WO2006079653A1 (en) 2005-01-31 2006-01-27 N-hydroxyamide derivatives and use thereof

Publications (2)

Publication Number Publication Date
EA200701636A1 true EA200701636A1 (ru) 2007-12-28
EA014238B1 EA014238B1 (ru) 2010-10-29

Family

ID=34938610

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701636A EA014238B1 (ru) 2005-01-31 2006-01-27 Производные n-гидроксиамида и их применение

Country Status (25)

Country Link
US (2) US7868009B2 (ru)
EP (1) EP1844032B1 (ru)
JP (1) JP4950070B2 (ru)
KR (1) KR20070105326A (ru)
CN (1) CN101208320B (ru)
AT (1) ATE516279T1 (ru)
AU (1) AU2006208781B2 (ru)
BR (1) BRPI0606756A2 (ru)
CA (1) CA2592154C (ru)
CY (1) CY1111743T1 (ru)
DK (1) DK1844032T3 (ru)
EA (1) EA014238B1 (ru)
ES (1) ES2369093T3 (ru)
HK (1) HK1115132A1 (ru)
HR (1) HRP20110529T1 (ru)
IL (1) IL184538A (ru)
MX (1) MX2007009231A (ru)
NO (1) NO20074458L (ru)
PL (1) PL1844032T3 (ru)
PT (1) PT1844032E (ru)
RS (1) RS51957B (ru)
SI (1) SI1844032T1 (ru)
UA (1) UA86862C2 (ru)
WO (1) WO2006079653A1 (ru)
ZA (1) ZA200705623B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090759A1 (en) * 2004-08-30 2008-04-17 Robert Kokenyesi Methods and kits for predicting risk for preterm labor
ZA200705623B (en) * 2005-01-31 2008-09-25 Serono Lab N-hydroxyamide derivatives and use thereof
EP2542078B1 (en) 2010-03-03 2015-10-07 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
GB9411598D0 (en) * 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
US20020115689A1 (en) 1999-12-21 2002-08-22 Joanne Waldstreicher Combination therapy for treating neurodegenerative disease
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
WO2001083461A1 (fr) 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Derives de thiazole et d'oxazole
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
CA2476012C (en) 2002-02-14 2011-04-19 Pharmacia Corporation Substituted pyridinones as modulators of p38 map kinase
GB0204159D0 (en) 2002-02-22 2002-04-10 British Biotech Pharm Metalloproteinase inhibitors
GB0208176D0 (en) * 2002-04-09 2002-05-22 Novartis Ag Organic compounds
AU2003266404B2 (en) 2002-09-24 2007-08-09 Novartis Ag Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
PL1771421T3 (pl) * 2004-07-26 2009-08-31 Serono Lab Pochodne N-hydroksyamidowe i ich zastosowanie
ZA200705623B (en) 2005-01-31 2008-09-25 Serono Lab N-hydroxyamide derivatives and use thereof

Also Published As

Publication number Publication date
NO20074458L (no) 2007-10-31
EA014238B1 (ru) 2010-10-29
IL184538A (en) 2013-02-28
US20080090838A1 (en) 2008-04-17
EP1844032A1 (en) 2007-10-17
HK1115132A1 (en) 2008-11-21
US8198280B2 (en) 2012-06-12
CN101208320B (zh) 2012-01-11
JP4950070B2 (ja) 2012-06-13
CY1111743T1 (el) 2015-10-07
DK1844032T3 (da) 2011-10-24
CA2592154C (en) 2014-03-18
SI1844032T1 (sl) 2011-09-30
US7868009B2 (en) 2011-01-11
KR20070105326A (ko) 2007-10-30
IL184538A0 (en) 2007-10-31
US20110086864A1 (en) 2011-04-14
CA2592154A1 (en) 2006-08-03
PT1844032E (pt) 2011-07-27
MX2007009231A (es) 2007-09-19
BRPI0606756A2 (pt) 2009-07-14
EP1844032B1 (en) 2011-07-13
HRP20110529T1 (hr) 2011-08-31
ES2369093T3 (es) 2011-11-25
CN101208320A (zh) 2008-06-25
ATE516279T1 (de) 2011-07-15
AU2006208781B2 (en) 2011-12-08
WO2006079653A1 (en) 2006-08-03
ZA200705623B (en) 2008-09-25
AU2006208781A1 (en) 2006-08-03
RS51957B (en) 2012-02-29
UA86862C2 (en) 2009-05-25
PL1844032T3 (pl) 2011-09-30
JP2008528553A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
EA201001127A1 (ru) Производные пиридина
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
EA200601223A1 (ru) Производные сульфонамида для лечения заболеваний
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
NO20061254L (no) Farmasoytiske blandinger
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
EP1737499A4 (en) TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
EA200701348A1 (ru) Сульфониламиноциклические соединения и их применение
EA200701636A1 (ru) Производные n-гидроксиамида и их применение
CY1112088T1 (el) Παραγωγα ν-υδροξυαμιδης και η χρηση τους
NO20070820L (no) Oktahydropyrrolo (2,3,C)pyridin-derivanter og farmasoytisk anvendelse derav.
UA88785C2 (en) N-hydroxyamide derivatives and use thereof
CY1112367T1 (el) Κυκλικα παραγωγα σουλφονυλ αμινο και χρηση αυτων ως μμρ αναστολεων

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU